CY1115269T1 - Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους - Google Patents
Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδουςInfo
- Publication number
- CY1115269T1 CY1115269T1 CY20141100469T CY141100469T CY1115269T1 CY 1115269 T1 CY1115269 T1 CY 1115269T1 CY 20141100469 T CY20141100469 T CY 20141100469T CY 141100469 T CY141100469 T CY 141100469T CY 1115269 T1 CY1115269 T1 CY 1115269T1
- Authority
- CY
- Cyprus
- Prior art keywords
- naloxone
- medicine
- preparation
- naltrexone
- therapeutic treatment
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000002860 competitive effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 abstract 2
- 229960004127 naloxone Drugs 0.000 abstract 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 abstract 2
- 229960003086 naltrexone Drugs 0.000 abstract 2
- 201000004569 Blindness Diseases 0.000 abstract 1
- 102000003840 Opioid Receptors Human genes 0.000 abstract 1
- 108090000137 Opioid Receptors Proteins 0.000 abstract 1
- 208000032400 Retinal pigmentation Diseases 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000004154 complement system Effects 0.000 abstract 1
- 238000004925 denaturation Methods 0.000 abstract 1
- 230000036425 denaturation Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000018769 loss of vision Diseases 0.000 abstract 1
- 231100000864 loss of vision Toxicity 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003887 narcotic antagonist Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 230000004393 visual impairment Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Οι εκφυλιστικές ασθένειες του αμφιβληστροειδούς επηρεάζουν την εύθραυστη στιβάδα του αμφιβληστροειδικού ιστού που επενδύει το εσωτερικό πίσω μέρος του οφθαλμού, οδηγώντας σε βαθμιαία απώλεια όρασης. Η χρήση ανταγωνιστών οπιοειδών για την παρασκευή ενός φαρμάκου για την εκλεκτική δέσμευση των τοποθεσιών οπιοειδών υποδοχέων του σώματος είναι μια μέθοδος αντιμετώπισης αυτής της ανθρώπινης πάθησης με ημερήσια χορήγηση στον ασθενή, από περίπου 0,5 έως περίπου 10 mg φαρμάκων, όπως ναλτρεξόνης, ναλοξόνης ή ναλμεφαίνης. Δρουν πρώτα μέσω κανονικοποίησης των αποδιατάξεων στο ανθρώπινο σύστημα συμπληρώματος που μπορεί να λάβουν χώρα στην αιτιολογία της ασθένειας. Στοχεύεται πρωταρχικά μια θεραπευτική προσέγγιση για τον εκφυλισμό της ωχράς κηλίδας και την μελαγχρωστική αμφιβληστροειδίτιδα. Από του στόματος, παρεντερικές χρήσεις, καθώς και τοπικές εφαρμογές, μπορεί όλα να εξετάζονται. Μπορεί να χορηγούνται σε μια ή σε διηρημένες δόσεις για την καλύτερη δραστικότητα δέσμευσης υποδοχέα, κατά προτίμηση στις βραδινές ώρες. Χαμηλής Δόσης Ναλτρεξόνη κατάλληλη για από του στόματος χορήγηση είναι η περισσότερο προτιμώμενη αγωγή περίπου στα 4,5 mg/ημέρα.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08807092.5A EP2379066B1 (en) | 2008-09-16 | 2008-09-16 | Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases |
| PCT/IB2008/002412 WO2010032073A1 (en) | 2008-09-16 | 2008-09-16 | Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115269T1 true CY1115269T1 (el) | 2017-01-04 |
Family
ID=41138810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100469T CY1115269T1 (el) | 2008-09-16 | 2014-06-26 | Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110165232A1 (el) |
| EP (1) | EP2379066B1 (el) |
| CY (1) | CY1115269T1 (el) |
| DK (1) | DK2379066T3 (el) |
| ES (1) | ES2475199T3 (el) |
| HR (1) | HRP20140596T1 (el) |
| PL (1) | PL2379066T3 (el) |
| PT (1) | PT2379066E (el) |
| SI (1) | SI2379066T1 (el) |
| WO (1) | WO2010032073A1 (el) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011040894A1 (en) | 2009-10-01 | 2011-04-07 | Mustafa Nevzat Ilaç Sanayii A.Ş. | Topical compositions of opioid antagonists and methods for treating skin conditions therewith |
| TR201002473A2 (tr) | 2010-03-31 | 2011-09-21 | Mustafa Nevzat �La� Sanay�� A.�. | Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi. |
| EP2568967B2 (en) | 2010-05-10 | 2022-07-27 | Euro-Celtique S.A. | Pharmaceutical compositions comprising hydromorphone and naloxone |
| BR112012028656A2 (pt) | 2010-05-10 | 2016-08-09 | Euro Celtique Sa | combinação de grânulos carregados ativos com ativos adicionais |
| WO2011141489A1 (en) | 2010-05-10 | 2011-11-17 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
| US20140213605A1 (en) * | 2013-01-27 | 2014-07-31 | Remedeye Inc. | Methods for treating eye disorders using opioid receptor antagonists |
| CA2929909C (en) | 2013-11-13 | 2018-08-21 | Euro-Celtique S.A. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4416886A (en) * | 1981-07-29 | 1983-11-22 | Dermall Limited | Method of treating pruritis and composition therefor |
| US4888346A (en) * | 1986-10-07 | 1989-12-19 | Bernard Bihari | Method for the treatment of persons infected with HTLV-III (AIDS) virus |
| US5356900A (en) * | 1986-10-07 | 1994-10-18 | Bernard Bihari | Method of treating chronic herpes virus infections using an opiate receptor antagonist |
| US4857533A (en) * | 1988-12-15 | 1989-08-15 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for autoimmune diseases |
| DE4222534A1 (de) * | 1992-07-09 | 1994-01-13 | Behringwerke Ag | Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6384044B1 (en) * | 1999-11-29 | 2002-05-07 | Bernard Bihari | Method of treating cancer of the prostate |
| US20030077301A1 (en) * | 1999-12-16 | 2003-04-24 | Maibach Howard I. | Topical pharmaceutical composition for the treatment of inflammatory dermatoses |
| US20030072724A1 (en) * | 1999-12-16 | 2003-04-17 | Maibach Howard I. | Topical pharmaceutical composition to treat hyperpigmentation of the skin |
| WO2001057184A2 (en) | 2000-02-01 | 2001-08-09 | Vanderbilt University | Use of platelet activity modulators for inhibiting complement activation |
| US20030191147A1 (en) * | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
| US6821523B2 (en) * | 2002-06-21 | 2004-11-23 | Dermatrends, Inc. | Topical administration of pharmacologically active bases in the treatment of warts |
| US20030235542A1 (en) * | 2002-06-21 | 2003-12-25 | Maibach Howard I. | Topical administration of pharmacologically active bases for skin lightening |
| AU2004229551A1 (en) * | 2003-04-14 | 2004-10-28 | Pain Therapeutics, Inc. | Methods for the treatment of pain comprising opioid antagonists |
| AU2004233846B2 (en) * | 2003-04-29 | 2010-07-01 | Nalpropion Pharmaceuticals Llc | Compositions for affecting weight loss |
| CA2580694A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| JP2006131545A (ja) * | 2004-11-05 | 2006-05-25 | Japan Science & Technology Agency | 神経因性疼痛治療剤 |
| EP1861096B1 (en) * | 2005-03-07 | 2018-12-26 | The University of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8916195B2 (en) * | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| US8828953B2 (en) * | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| US8829020B2 (en) * | 2009-07-16 | 2014-09-09 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
| WO2011040894A1 (en) * | 2009-10-01 | 2011-04-07 | Mustafa Nevzat Ilaç Sanayii A.Ş. | Topical compositions of opioid antagonists and methods for treating skin conditions therewith |
| TR201002473A2 (tr) * | 2010-03-31 | 2011-09-21 | Mustafa Nevzat �La� Sanay�� A.�. | Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi. |
-
2008
- 2008-09-16 PT PT88070925T patent/PT2379066E/pt unknown
- 2008-09-16 SI SI200831236T patent/SI2379066T1/sl unknown
- 2008-09-16 ES ES08807092.5T patent/ES2475199T3/es active Active
- 2008-09-16 US US13/119,191 patent/US20110165232A1/en not_active Abandoned
- 2008-09-16 PL PL08807092T patent/PL2379066T3/pl unknown
- 2008-09-16 EP EP08807092.5A patent/EP2379066B1/en not_active Not-in-force
- 2008-09-16 DK DK08807092.5T patent/DK2379066T3/da active
- 2008-09-16 WO PCT/IB2008/002412 patent/WO2010032073A1/en active Application Filing
- 2008-09-16 HR HRP20140596AT patent/HRP20140596T1/hr unknown
-
2014
- 2014-06-26 CY CY20141100469T patent/CY1115269T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2379066T3 (pl) | 2014-09-30 |
| WO2010032073A1 (en) | 2010-03-25 |
| ES2475199T3 (es) | 2014-07-10 |
| PT2379066E (pt) | 2014-07-04 |
| EP2379066A1 (en) | 2011-10-26 |
| HRP20140596T1 (hr) | 2014-08-01 |
| DK2379066T3 (da) | 2014-06-30 |
| SI2379066T1 (sl) | 2014-08-29 |
| US20110165232A1 (en) | 2011-07-07 |
| EP2379066B1 (en) | 2014-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115269T1 (el) | Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους | |
| Giacoppo et al. | Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation | |
| CY1117916T1 (el) | Θεραπεια διαταραχων που σχετιζονται me bdnf χρησιμοποιωντας laquinimod | |
| Keservani et al. | Design and fabrication of transdermal/skin drug-delivery system | |
| ES2241651T3 (es) | Utilizacion de la nicotina o de sus derivados y de la l-dopa en un medicamento destinado al tratamiento de enfermedades neurologicas, especialmente la enfermedad de parkinson. | |
| JP2006501240A5 (el) | ||
| CY1113253T1 (el) | Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη | |
| TW200806318A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
| KR101900520B1 (ko) | 복합 조성물 | |
| TW201249425A (en) | Cannabinoids for use in the treatment of neuropathic pain | |
| WO2008067991A3 (en) | Skin-friendly drug complexes for transdermal administration | |
| WO2016116280A1 (en) | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| US20190192525A1 (en) | Apilimod compositions and methods for using same | |
| JP2016521755A5 (el) | ||
| ES2704987T3 (es) | Composiciones farmacéuticas para terapia de combinación | |
| BRPI0804623A2 (pt) | uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos | |
| BR9913746F1 (pt) | derivado de piridínio, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, processo para preparação de uma formulação parenteral, e, métodos de tratamento de um paciente diabético e de prevenção ou de tratamento de doenças causadas por diabetes e por complicações relacionadas com o envelhecimento | |
| JP2013501805A (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| WO2010129340A3 (en) | Novel photosensitizer formulations for oral administration | |
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| WO2008120966A1 (es) | Composición farmacéutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgésico opiáceo para el manejo del dolor. | |
| EA200970562A1 (ru) | Применение l-карнитина для получения лекарственного средства в форме глазных капель для лечения заболеваний роговицы | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| FI3519050T3 (fi) | Koostumuksia silmätautien hoitamiseksi |